Ascendis Pharma A/S’s (ASND) “Outperform” Rating Reaffirmed at Wedbush

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report issued on Friday,RTT News reports. They currently have a $181.00 price objective on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 45.64% from the stock’s previous close.

ASND has been the topic of a number of other research reports. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. TD Cowen boosted their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Finally, StockNews.com cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.54.

Ascendis Pharma A/S Trading Down 1.4 %

Shares of ASND stock opened at $124.28 on Friday. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The company has a market capitalization of $7.54 billion, a price-to-earnings ratio of -13.35 and a beta of 0.66. The firm has a 50-day moving average price of $132.15 and a 200 day moving average price of $132.80.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, research analysts predict that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the last quarter. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth approximately $205,000. Rhumbline Advisers raised its position in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Finally, Pursue Wealth Partners LLC acquired a new position in Ascendis Pharma A/S in the third quarter worth $217,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.